CagriSema.

Activating the GLP-1 receptor to enhance insulin release, slow gastric emptying, and reduce appetite.

Glucagon-like peptide-1 is an incretin hormone released from the gut after a meal. Its receptor is a class B G-protein-coupled receptor found on pancreatic beta cells, on stomach and gut tissue, and on neurons in the hypothalamus and brainstem, including the area postrema. When the receptor is activated, three things happen at once. Beta cells become more responsive to glucose, so insulin secretion rises mainly when blood glucose is already elevated rather than continuously, which is why this class carries a lower intrinsic hypoglycaemia risk than insulin itself. The stomach empties more slowly, flattening the rise in glucose after eating and prolonging the sense of fullness. Central appetite circuits shift toward satiety, reducing the drive to eat between meals. Glucagon secretion is also suppressed when glucose is high. Many compounds target this receptor because native GLP-1 is degraded within minutes by dipeptidyl peptidase-4. Almost every design problem in the class is a half-life problem, and the answers differ. Some analogs attach a fatty-acid chain so the molecule binds albumin and circulates far longer. Others alter the amino acids around the cleavage site so the enzyme cannot act. These structural choices set how often a compound is given and how steeply blood levels rise and fall, which in turn shapes how much nausea a person experiences during the early adjustment period. The class also splits by how many receptors a molecule touches. Pure GLP-1 agonists engage this pathway alone. Dual and triple agonists add GIP, glucagon, or amylin activity on top of it, and combination products pair a GLP-1 agonist with a separate molecule. In every case the GLP-1 arm remains the backbone of the metabolic effect. Of all the pathways described on this site, this one has the strongest and most mature clinical footing. Several GLP-1 receptor agonists are approved medicines for type 2 diabetes, for obesity, or both, and the mechanism has been characterised in humans rather than inferred from animal work. That does not make every molecule in the class equivalent. Some listed here are still investigational, and their receptor activity being well understood says nothing about whether their particular formulation, purity, or long-term profile has been established.

Activating amylin and calcitonin-family receptors to promote meal-ending satiation.

Amylin, also called islet amyloid polypeptide, is co-secreted with insulin from pancreatic beta cells in response to a meal. It does not act through a dedicated single receptor. Instead, amylin receptors are heterodimers formed when the calcitonin receptor associates with one of three receptor-activity-modifying proteins, known as RAMP1, RAMP2, and RAMP3. The pairing changes the receptor's pharmacology, so the same core receptor becomes amylin-responsive depending on which accessory protein it partners with. These complexes are concentrated in hindbrain structures, particularly the area postrema and nucleus tractus solitarius, and in hypothalamic circuits. Activating them produces satiation rather than appetite suppression in the broader sense. The distinction matters. Amylin signalling is the physiological brake that ends a meal, reducing the size of individual eating occasions and slowing gastric emptying, and it also suppresses glucagon after eating. Preclinical work suggests amylin signalling additionally influences leptin sensitivity, which is interesting because leptin resistance is one of the standard explanations for why weight regain is so common. Native amylin is impractical as a drug: it is prone to aggregating into insoluble fibrils, which is the same tendency that produces amyloid deposits in the pancreas in type 2 diabetes. Analogs are therefore engineered for solubility and stability, and long-acting versions add modifications that extend circulation time enough for infrequent administration. Compounds in this group differ mainly in that engineering and in whether they are used alone or paired with a GLP-1 receptor agonist in a fixed combination. The reason for combining the two is that amylin and GLP-1 act on overlapping but distinct circuits, so their effects on food intake can add together rather than simply duplicating each other. That is the explicit design logic behind the combination products in this group. The pathway's clinical standing is intermediate. Amylin biology itself is well established, and an earlier short-acting amylin analog has been an approved medicine for years, so the mechanism is not speculative. The long-acting analogs described here, however, are still working through late-stage clinical development, and their durable benefit and tolerability relative to GLP-1 agonism alone are not yet settled questions. Nausea and vomiting are recognised features of amylin receptor activation, reflecting the same hindbrain circuitry that produces the satiation effect, so the wanted and unwanted effects are not easily separated.

The Phase 3 trial in adults with obesity without diabetes reported roughly that magnitude at 68 weeks.

The open-label head-to-head trial did not meet its primary non-inferiority endpoint against tirzepatide.

It remains investigational, with a US application filed and no approval granted.

The diabetes trial showed weight and glycemic benefit versus placebo, but weight loss was more modest in that population.

Gastrointestinal events dominated the adverse-event profile, and the semaglutide component carries a boxed thyroid C-cell warning.